drugset / Trial / NCT05615636
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RandomizedSingle-groupOpen-labelTreatment
Summary
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.
Timeline
- Start
- 2023-04-28
- Primary completion
- 2027-08-19
- Completion
- 2027-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Mosunetuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Polatuzumab Vedotin | Other / unclassified | — | Intravenous |
| Subject | Tafasitamab | Monoclonal antibody | — | Intravenous |